IOVA Iovance Biotherapeutics Inc

$2.69

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company is headquartered in San Carlos, California.

Website: https://www.iovance.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1425205
Address
999 SKYWAY ROAD, SUITE 150, SAN CARLOS, CA, US
Valuation
Market Cap
$1.00B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
1.41
Performance
EPS
$-1.28
Dividend Yield
Profit Margin
-226.80%
ROE
-57.50%
Technicals
50D MA
$4.10
200D MA
$7.71
52W High
$14.23
52W Low
$2.70
Fundamentals
Shares Outstanding
328M
Target Price
$19.18
Beta
1.04

IOVA EPS Estimates vs Actual

Estimated
Actual

IOVA News & Sentiment

Aug 22, 2025 • GlobeNewswire NEUTRAL
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 )
SAN CARLOS, Calif., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc. ( NASDAQ: IOVA ) ( "Iovance" or the "Company" ) , a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ( "TIL" ) therapies for patients with ...
Aug 22, 2025 • Benzinga NEUTRAL
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635 ( c ) ( 4 ) - Iovance Biotherapeutics ( NASDAQ:IOVA )
SAN CARLOS, Calif., Aug. 22, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Aug 19, 2025 • Motley Fool SOMEWHAT-BULLISH
Why Iovance Biotherapeutics Stock Was Climbing Today
One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country.
Aug 19, 2025 • Benzinga SOMEWHAT-BULLISH
Intel, Plymouth Industrial REIT, Premier And Other Big Stocks Moving Higher On Tuesday - Heartland Express ( NASDAQ:HTLD ) , Intel ( NASDAQ:INTC )
U.S. stocks were mixed, with the Dow Jones index gaining more than 150 points on Tuesday. Shares of Intel Corporation INTC rose sharply during Tuesday's session after it was announced that Softbank will invest $2 billion in the company.
Aug 19, 2025 • Benzinga SOMEWHAT-BULLISH
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket - Color Star Tech ( NASDAQ:ADD ) , Adecoagro ( NYSE:AGRO )
Shares of Palo Alto Networks, Inc. PANW rose sharply in pre-market trading as the company reported better-than-expected financial results for the fourth quarter of fiscal 2025 and issued strong guidance for fiscal 2026 after the market closed on Monday.
Aug 18, 2025 • Benzinga NEUTRAL
Iovance's Amtagvi® ( lifileucel ) Receives Health Canada Approval for Advanced Melanoma - Iovance Biotherapeutics ( NASDAQ:IOVA )
First T cell therapy for a solid tumor cancer and first treatment option approved in Canada for advanced melanoma after anti-PD-1 and targeted therapy SAN CARLOS, Calif., Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- Iovance Biotherapeutics, Inc.
Sentiment Snapshot

Average Sentiment Score:

0.064
50 articles with scored sentiment

Overall Sentiment:

Neutral

IOVA Reported Earnings

Feb 26, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.27
  • Whisper:
  • Surprise %: 2.8%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.28
  • Estimate: $-0.30
  • Whisper:
  • Surprise %: 6.7%
Aug 08, 2024
Jun 30, 2024 (Post market)
0.01 Surprise
  • Reported EPS: $-0.34
  • Estimate: $-0.35
  • Whisper:
  • Surprise %: 2.9%
May 09, 2024
Mar 31, 2024 (Post market)
0.0 Surprise
  • Reported EPS: $-0.42
  • Estimate: $-0.42
  • Whisper:
  • Surprise %: 0.0%
Feb 28, 2024
Dec 31, 2023 (Post market)
-0.02 Surprise
  • Reported EPS: $-0.45
  • Estimate: $-0.43
  • Whisper:
  • Surprise %: -4.7%
Nov 07, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.46
  • Estimate: $-0.45
  • Whisper:
  • Surprise %: -2.2%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.33 Surprise
  • Reported EPS: $-0.47
  • Estimate: $-0.80
  • Whisper:
  • Surprise %: 41.2%
May 09, 2023
Mar 31, 2023 (Post market)
0.24 Surprise
  • Reported EPS: $-0.50
  • Estimate: $-0.74
  • Whisper:
  • Surprise %: 32.4%
Feb 28, 2023
Dec 31, 2022 (Post market)
0.0 Surprise
  • Reported EPS: $-0.64
  • Estimate: $-0.64
  • Whisper:
  • Surprise %: 0.0%

Financials